Parkman Healthcare Partners’s UroGen Pharma URGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.94M Buy
275,000
+106,232
+63% +$2.13M 0.51% 55
2025
Q4
$3.95M Sell
168,768
-233,827
-58% -$5.07M 0.38% 70
2025
Q3
$8.03M Buy
402,595
+225,893
+128% +$4.06M 0.88% 43
2025
Q2
$2.42M Sell
176,702
-216,451
-55% -$2.08M 0.28% 78
2025
Q1
$4.35M Buy
393,153
+23,292
+6% +$248K 0.52% 56
2024
Q4
$3.94M Buy
369,861
+22,320
+6% +$267K 0.52% 52
2024
Q3
$4.41M Buy
347,541
+73,076
+27% +$1.08M 0.56% 57
2024
Q2
$4.61M Buy
274,465
+90,281
+49% +$1.28M 0.63% 57
2024
Q1
$2.76M Buy
184,184
+8,684
+5% +$142K 0.34% 74
2023
Q4
$2.63M Buy
175,500
+30,189
+21% +$392K 0.37% 68
2023
Q3
$2.04M Buy
+145,311
New +$2.33M 0.37% 73

Other funds holding URGN